| Assessment Status | Awaiting HTA submission from Applicant |
| HTA ID | 22042 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Is indicated for the adjuvant treatment of adults and adolescent (≥12 years) with stage IIB or IIC melanoma following complete resection. |
| Assessment Process | |
| Rapid review commissioned | 22/06/2022 |
| Rapid review completed | 14/07/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/07/2022 |
| Pre-submission consultation with Applicant | 15/11/2022 |
